STUDIO

Cereno granted approval to initiate  Phase I trial with CS014

Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”

Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted...

RECOMMENDED READING

Biosergen_firstpatient

Biosergen on dosing the first patient with life-threatening fungal disease

The first patient has been dosed in Biosergen’s clinical phase Ib trial with BSG005,...
Phase Holographic Imaging to list in the US

PHI aims for US listing

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing...

EVENT